The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors

Cancer cells bearing distinct KRAS mutations exhibit variable sensitivity to SHP2 inhibitors (SHP2i). Here we show that cells harboring KRAS Q61H are uniquely resistant to SHP2i, and investigate the underlying mechanisms using biophysics, molecular dynamics, and cell-based approaches. Q61H mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Gebregiworgis, Teklab, Kano, Yoshihito, St-Germain, Jonathan, Radulovich, Nikolina, Udaskin, Molly L., Mentes, Ahmet, Huang, Richard, Poon, Betty P. K., He, Wenguang, Valencia-Sama, Ivette, Robinson, Claire M., Huestis, Melissa, Miao, Jinmin, Yeh, Jen Jen, Zhang, Zhong-Yin, Irwin, Meredith S., Lee, Jeffrey E., Tsao, Ming-Sound, Raught, Brian, Marshall, Christopher B., Ohh, Michael, Ikura, Mitsuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560773/
https://www.ncbi.nlm.nih.gov/pubmed/34725361
http://dx.doi.org/10.1038/s41467-021-26526-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560773/
https://www.ncbi.nlm.nih.gov/pubmed/34725361
http://dx.doi.org/10.1038/s41467-021-26526-y

Ejemplares similares